CD8A and cancer: The demonstrated role of SA-4-1BBL in the generation of both CD8+ T and NK cell effector responses against tumor [10,13], combined with its ability to prevent the conversion of Tconvs into pTregs and overcome Treg suppression, as reported herein, demonstrate the significant potential of this molecule for cancer immunotherapy and other indications where excessive frequency of Tregs contributes to pathology.